NFIA-AS2

Summary

NFIA-AS2 (NFIA antisense RNA 2, HGNC:40401) is a long non-coding RNA gene on chromosome 1p31.3.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:40401
Approved symbol	NFIA-AS2
Name	NFIA antisense RNA 2
Location	1p31.3
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000237928
Ensembl biotype	lncRNA
Entrez	100996570
RNAcentral	URS00022AE7C0 — lncRNA, 1234 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 lncRNA

ENST00000418662, ENST00000421455, ENST00000438559, ENST00000655960, ENST00000665665, ENST00000718596, ENST00000736900

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000418662 — 3 exons

Exon	Start	End
ENSE00001639560	60952511	60952849
ENSE00001752574	60941180	60941252
ENSE00001779342	60940395	60940631

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 79.05.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3813 / max 102.6672, expressed in 71 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12601	0.3656	67
12600	0.0157	5

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	79.05	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.65	gold quality
myocardium	UBERON:0002349	71.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.91	gold quality
ganglionic eminence	UBERON:0004023	70.37	gold quality
nasal cavity epithelium	UBERON:0005384	69.92	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	68.46	gold quality
quadriceps femoris	UBERON:0001377	67.51	gold quality
hindlimb stylopod muscle	UBERON:0004252	67.17	gold quality
apex of heart	UBERON:0002098	67.08	gold quality
vastus lateralis	UBERON:0001379	66.95	gold quality
skeletal muscle tissue	UBERON:0001134	65.13	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	64.93	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	63.85	gold quality
muscle tissue	UBERON:0002385	63.73	gold quality
descending thoracic aorta	UBERON:0002345	63.68	gold quality
heart right ventricle	UBERON:0002080	63.26	gold quality
biceps brachii	UBERON:0001507	62.98	gold quality
cortical plate	UBERON:0005343	62.97	gold quality
spinal cord	UBERON:0002240	62.96	gold quality
thyroid gland	UBERON:0002046	61.66	gold quality
hypothalamus	UBERON:0001898	61.55	gold quality
right lobe of thyroid gland	UBERON:0001119	61.49	gold quality
left lobe of thyroid gland	UBERON:0001120	61.48	gold quality
thoracic aorta	UBERON:0001515	61.39	gold quality
substantia nigra	UBERON:0002038	61.38	gold quality
ascending aorta	UBERON:0001496	61.10	gold quality
right atrium auricular region	UBERON:0006631	61.09	gold quality
cardiac atrium	UBERON:0002081	60.92	gold quality
midbrain	UBERON:0001891	60.77	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.26

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis. (PMID:32779154)
• HIF-1alpha and NFIA-AS2 Polymorphisms as Potential Determinants of Total Hemoglobin Mass in Endurance Athletes. (PMID:35622109)
• Identification and characterization of the long non-coding RNA NFIA-AS2 as a novel locus for body mass index in American Indians. (PMID:36806387)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.